Investment in the CGT Catapult to Boost UK ATMP Production

Working with the Cell and Gene Therapy Catapult Stevenage, which offers capability for setup of Advanced Therapy Medicinal Products (ATMP) manufacturing at scale, GSK is set to accelerate its cell and gene therapy pipeline for clinical trials. The agreement represents a successful step in the growth of cell and gene therapy activities in Stevenage and the UK as a whole. The additive experience of GSK will help to boost further new capabilities that will benefit other users already present and progressing their manufacturing onsite, as well as future applicants.

Tony Wood, Senior Vice President, Medicinal Science and Technology of GSK commented:

“The UK already has significant capabilities in cell and gene therapy, and this agreement illustrates how strategic investments by GSK can make them even stronger. Working more closely with CGT Catapult will help us advance our promising cell and gene therapy programmes, and bring these transformative medicines more quickly to the patients who desperately need them.”

Matthew Durdy, Chief Executive Officer of Cell and Gene Therapy Catapult commented:

“The move by a leading pharmaceutical company like GSK to establish ATMP manufacturing capabilities at the CGT Catapult facility in Stevenage highlights the UK’s globally leading position for large and smaller organisations alike to develop, manufacture and deliver cell and gene therapies. With a range of collaborators already based in the facility, we look forward to participating in the collective innovation onsite to pioneer the growth in scale of advanced therapy manufacturing.”